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It is well accepted that cancer cells have different 
metabolic programme compared to normal cells (1). 
Rapidly replicating tumor cells requirements to support 
inappropriate cell proliferation and maintain growth is 
reflected at least in part by a metabolic shift towards aerobic 
glycolysis, a phenomenon known as Warburg effect and a 
modification in gene expression for enzymes involved in 
other pathways supporting proliferation (2,3). Increased 
glucose uptake lead to modifications of many metabolites 
mainly associated with cell growth and stress (4,5). 
Currently, still little is known about the mechanisms 
linking deregulated metabolism and cancer aggressiveness. 
Prostate cancer (PCa) is a particularly suitable model to 
investigate this aspect. In fact, healthy prostate exhibit 
a unique metabolism, leading to production of the 
components of prostatic fluid: prostate specific antigen 
(PSA), spermine, myo-inositol, and citrate. Such a 
physiological condition is completely altered in neoplastic 
cells due to the alteration of glandular framework, leading 
to zinc loss and subsequently citrate accumulation. 
Therefore, prostate tumors display unique metabolomic 
signature (6).
Khan et al. (7) analyzed global metabolic profiling of 
benign and malignant prostate, allowing the creation of 
a comprehensive catalog of metabolic alterations. Such 
analysis allows not only a better understanding of biological 
basis of tumor development and progression, but also 
a platform for the identification of metabolites such as 
sarcosine, uracil, kynurenine, glycerol-3-phosphate, leucine 
and proline, which increase with disease progression and 
may represent new diagnostic and prognostic biomarkers. 
Metabolomic analysis of biological fluids are minimally 
invasive and easily accessible, providing a potential useful 
tool for cancer diagnosis and prognosis. Previously reports 
indicated citrate, myo-inositol and the polyamine spermine 
as metabolic markers of PCa in prostatic secretions (8) and 
metabolic differences between PCa patients and healthy 
subjects blood samples (9,10).
Increased glucose use by cancer cells is the basis for 
cancer detection by the uptake of the glucose analogue, 
fluorine-18-labeled 2-deoxy-2-fluoro-D-glucose (18F-FDG) 
which can be visualized by positron-emission tomography 
(PET). PCa cells have a dominant uptake of fatty acid 
over glucose, alternative tracers have been proposed and 
PET scanning in PCa is still developing (11). Imaging 
with PET tracers with 11C acetate and 11C choline have 
shown sufficient sensitivity in the detection not only of 
primary site, but also of metastasis and recurrence (12). 
Unfortunately, both of the tracers were not able to reveal 
small metastatic sites (13). Of note, the study of altered 
metabolic pathway in PCa led to the identification of 
potential therapeutic target. Particular attention has 
received key lipogenic enzymes, such as Fatty acid synthase 
(FASN) and 5’ adenosine monophosphate-activated protein 
kinase (AMPK). It has been recently demonstrated a 
decreased of PCa onset among subjects taking statin in the 
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Finnish Prostate Cancer Screening Trial, independently of 
circulating PSA values (14). Metformin is a derivative of 
guanidine and is able to activate AMPK, partly explaining 
its anti-tumor effect. Accordingly, several trials treating 
patients with a combination of chemotherapeutic agents 
and metformin in low risk PCa patients has been planned. 
Recent studies indicated that patients receiving metformin 
together with androgen deprivation therapy (ADT) have 
benefits in terms of cell proliferation beyond metabolic 
phenotype (15).
Overall, literature data suggest that targeting lipid 
metabolism provides an interesting road to take. Metabolic 
reprogramming of PCa cell represents a promising way to 
explore investigation for the identification of new diagnostic 
and therapeutic strategies in PCa (Figure 1), as shown 
by the results obtained by Liss et al. (16). Particularly, 
worthy of attention seems to be fatty acid metabolism 
studies, potentially able to provide in future useful tools for 
personalized medicine.
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Figure 1 Metabolic reprogramming in prostate cancer cell has diagnostic and therapeutic implications.
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